Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 10/20 | 0.65 |
| ▸ | CALCR | P30988 | 10/20 | 0.65 |
| ▸ | MC4R | P32245 | 2/20 | 0.62 |
| ▸ | MC5R | P33032 | 2/20 | 0.62 |
| ▸ | MC3R | P41968 | 2/20 | 0.62 |
| ▸ | MC1R | Q01726 | 2/20 | 0.62 |
| ▸ | TFPI | P10646 | 4/20 | 0.61 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | CTSH | P09668 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14096140 | 0.94 | RAMP3 (0.60) | RAMP3CALCRMC4RMC5RMC3R | |
| SCHEMBL10065713 | 0.89 | RAMP3 (0.61) | RAMP3CALCRTFPI | |
| SCHEMBL12984377 | 0.89 | CTSL (0.55) | RAMP3CALCRMC4RMC5RMC3R | |
| SCHEMBL10065575 | 0.89 | CTSL (0.55) | RAMP3CALCRMC4RMC5RMC3R | |
| SCHEMBL12984102 | 0.85 | RAMP3 (0.66) | RAMP3CALCRMC4RMC5RMC3R | |
| SCHEMBL13028816 | 0.83 | TFPI (0.62) | RAMP3CALCRMC4RMC5RMC3R | |
| SCHEMBL31014198 | 0.83 | MAPK8 (0.56) | CALCRTFPICTSLCTSSCTSK | |
| SCHEMBL13027243 | 0.82 | RAMP3 (0.62) | RAMP3CALCRMC4RMC5RMC3R | |
| SCHEMBL25027403 | 0.81 | MAPK8 (0.53) | CALCRTFPI | |
| Gfttgrrgdlatihgmnrpf SCHEMBL29847206 | 0.81 | NPY2R (0.66) | RAMP3CALCRTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316563-A1 | Method For The Preparation Of New Oligoclonal Antibodies | BRACCO IMAGING S.P.A. (IT) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316563-A1 | Method For The Preparation Of New Oligoclonal Antibodies | APOB, APOL1, FCGR3B | RAMP3 3589/4885CALCR 1054/4885MC4R 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.